Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast, Q3'25

By Inderes11/5/2025, 8:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Sofia Heigis
00:01 - 02:51

Hi everyone, and welcome to the presentation of Oncopeptides' report for the third quarter of 2025. My name is Sofia Heigis and I am the CEO of Oncopeptides. As we have increased our shareholder base over the last quarter, I wish to welcome both old and new shareholders to this earnings call. This is our standard disclaimer, as usual, I'm joined by our CFO, Henrik Bergentoft, and together we'll present our financial and operational performance for the third quarter. The third quarter was a strategically important period for Oncopeptides, as we knew we would have to demonstrate resilience in execution given the vacation period. Net sales reached 20.2 million, representing a 174% increase year over year and marking our fourth consecutive quarter over quarter growth. In July, we delivered an all-time high, which was followed by another all-time high in September. In between, we saw a seasonal slowdown typical during the European vacation period. All in all, we saw a quarter of growth, which results were stronger than the same period in 2024. So even though we are still sensitive to seasonal effects, this is a sign of how we have strengthened our position and advanced our launch. Our cash position at the end of the period was 147.9 million SEK, reflecting the successful completion of a rights issue of 150 million SEK, which was oversubscribed by 157%. The strong investor interest underlines confidence in our long-term strategy and provides the financial flexibility to continue building momentum while advancing our partnering discussions, including ongoing negotiations in Japan. On the scientific side. Pepaxti continued to gain credibility and recognition, and following its inclusion in the EHA clinical guidelines earlier this year, new independent publications and real-world presentations at the EHA Annual Meeting have further reinforced Pepaxti's efficacy and tolerability in real-life use. We also saw continued commercial traction in all our key European markets, with Italy leading the growth, Spain reaching full regional access, and Germany demonstrating more resilience than in previous years. During the same period. In short, a resilient and strategically important quarter that positions us well for a strong finish to 2025. I'll now hand over to Henrik for a closer look at the financials.

Henrik Bergentoft
02:52 - 06:45

Thank you so much, Sofia. So let's start with the financial summary for the third quarter of 2025. As mentioned, net sales increased to 20.2 million, a 174% growth compared to last year. Excluding the milestone payment from the South Korea licensing deal in 2024, this demonstrates significant top-line momentum. The gross profit reached 19.9 million, reflecting a robust gross margin of 99%, which underscores the strength and scalability of our business model. Operating expenses decreased by about 3% for both the quarter and the nine-month period, demonstrating our continued focus on cost control as a direct function of sales growth. Our EBIT improved from -61.3 million last year to -47.1 million this quarter. The net profit amounted to -60.9 million, highlighting that this includes net financial items impacted by the non-cash fair valuation of warrants amounting to -10.6 million. Overall, these results demonstrate strong revenue growth and improved cost efficiency, despite ongoing investments in our operations altogether, taking us towards the next platform of being profitable by the end of 2026. Looking at operating expenses, our quarterly sales and marketing costs increased from 29.8 million in 2024 to 30.1 million in 2025. This reflects our expansion efforts with the completion of our organization in Spain and Germany last year, and the establishment of our Italian organization this year. General and administrative costs rose just slightly from 18.4 to 19 million this year. Research and development costs decreased from 21.9 million to 17.3 million. As we currently have no ongoing clinical studies. However, we are still advancing our pre-clinical portfolio. All combined, the cost trends show our commitment to strategic, cost-conscious growth while maintaining discipline in our R&D spending. Turning to liquidity, our cash position at the end of Q3 amounted to 148 million SEK. Following the successful rights issue in the third quarter, which was oversubscribed at 157% and injected approximately 150 million SEK before issue-related costs, our liquidity is now estimated to last until we become cash flow positive at the end of 2026, assuming continued sales growth. We certainly are proud to have attracted such interest from both existing and new shareholders in the rights issue. So ending up with some key takeaways from the financial perspective, the company is delivering rapid revenue growth and maintaining exceptional gross margins. Cost control measures are yielding results, with operating expenses trending down. Meanwhile, revenue is growing. Liquidity is strong, and the recent capital raise provides a runway for continued execution and growth. The business is well positioned to achieve positive cash flow by the end of 2026, assuming our ongoing sales momentum. That concludes the financial presentation, and I'll hand it back over to you again, Sylvia.

Sofia Heigis
06:45 - 23:44

Research and development costs decreased from 21.9 million to 17.3 million. Henrik. Let's now turn to the commercial side, where we continue to build strong momentum across Europe and make real progress towards our long-term goal of profitability. We have seen a strong growth trajectory in the last three quarters, and our European business continues to grow, supported by positive clinical experience and peer-to-peer recommendations. Looking back, the third quarter is always affected by the vacation period, which is why it is encouraging to see growth and increased demand now in Q3 2025. It's a clear sign of more markets contributing to our revenue stream following the inclusion of the EU guidelines in July. Pepaxti has gained further recognition from leading myeloma experts. This type of validation has a tangible effect in the field. It strengthens awareness, drives clarity on the positioning of Pepaxti, and generates confidence among HCPs, which leads to new prescribers through peer-to-peer recommendations. All these factors are critical to our launch success, which support us in making a real difference for more and more patients, which in turn, drives uptake to generate shareholder value. We continue to build Oncopeptides around the European opportunity for Pepaxti, which we estimate at roughly 1.5 billion SEK annually. There are, however, patients in need of Pepaxti also in the rest of the world, and we are working with current partners and finding new partners to address that unmet need and add revenue streams. The long-term value will be generated from our pipeline, which we are advancing in the pre-clinical setting with several exciting assets getting closer to the clinic outside of Europe. Our focus remains on concluding a partnership for Japan. Discussions are advancing well but take a lot of time due to internal processes and governance, and we are still in the late stage of the due diligence phase. The structure of the potential agreement follows market practice, including upfront and milestone payments and double-digit royalties, with the partner assuming all costs related to regulatory and commercial activities in Japan. Japan represents a market roughly the size of Germany, with a well-defined path to approval agreed with the Japanese regulatory authorities and key opinion leaders supporting the unmet need for Pepaxti. We are focused on concluding a deal that is mutually beneficial for both us and our partner, which will naturally also benefit patients in Japan. Let's move to an update on our European key markets. Regarding market access, we have seen some very positive progress for Irish patients lately. We had an early access program open to ensure HCPs could gain experience, to assess if they would support the unmet need for Pepaxti in Ireland. This support is critical to enable us to enter into price negotiations. Ireland is a small and centralized market, and in a fairly short time, we have seen 12 patients being included in the EAP program. The data that has been submitted to the payer authority is very encouraging and KOLs are supporting the need, which once more confirms that Pepaxti delivers at or even beyond expectations in real life. We are discussing with HCPs in Ireland to publish the very encouraging data that they have generated, which can also support launches in other markets. We are hopeful that the strong evidence leads to access, but having said that, it commonly takes time and is usually very difficult to gain in Ireland. We expect to know more within the coming quarters. As already mentioned, we hit an all-time high demand in July, followed by another all-time high demand in September. The vacation period in Europe, particularly in August, is temporarily affecting net sales growth. I will get more into details per country in a short while. Important to note is that by the end of Q3, more than 550 patients have been treated since launch, and we are now truly making a difference for many patients in Europe with rare disease launches. It is not only the effort of the company, but all launches are dependent on peer-to-peer recommendations. These can originate from our own experience, published real-world data, or guidelines as some of the most important sources for such recommendations. And as already mentioned in the last quarter, we saw great progress in these areas. Yes, we have two real-world data sets published and presented at the International Myeloma Society. We achieved the inclusion of Pepaxti in the updated EMA guidelines in July, securing a strong recommendation in our desired position, which is excellent as these guidelines are now being referenced across Europe. One more important aspect for the mid and long-term delivery of the launch is to close evidence gaps. That appears due to how the treatment landscape evolves, and it can support differentiation and inform treatment decisions over time. As a small company, we don't see a return on investment in setting up our own studies to close these gaps, but we do invest in ideas that fit our strategy coming from external investigators. This type of study is very cost-effective for us and generates scientific engagement, which is also important for the launch. Here we see increased interest from KOLs to generate data on Pepaxti and the PDC platform, and we now have investigator-initiated trials contracted in all markets. Here is a heatmap illustrating the sales growth across Europe in Q3 compared to previous quarters, and I will now get into more details per market. Germany remains our largest market. It's the market most affected by the vacation period. And when we look at our segment, we can conclude via sales data that the vacation period is affecting the overall multiple myeloma market. We also observed a decline in demand in August. This is also the case for Pepaxti. We anticipated this and are looking to catch up in Q4. Given the slowness in the market, it's important and encouraging to see how we are continuously broadening the prescriber base. Increased experience in Germany has led to several RWD publications being generated currently. The effect on T cells is being explored further, illustrating how Pepaxti is differentiated from other alkylators by affecting not only the nuclear DNA but also the mitochondrial DNA. These are important scientific questions that will advance our scientific understanding and fuel our launch. In addition, we have several proposals under review from German KOLs, which demonstrate the increased interest in Pepaxti and the PDC platform, interest that we actually lacked at launch. These are very encouraging signs. As these studies have the potential to close important evidence gaps that can support our launch in the mid and long term and also support our pipeline development. Finally, we do see good progress in awareness, which was confirmed and boosted by the annual German-speaking Hematology Congress taking place now in October. The majority of companies are focused on immunotherapy and early lines of treatment. And our symposium, which focused on real-life patients who are older and frailer than those in the clinical trials, attracted so many participants that we had to use the overflow room to accommodate everyone. This is a sign that there is a great interest in and need to discuss the target patient profile of Pepaxti, highlighting the necessity to complement immunotherapy. As mentioned, it's encouraging to see that quarter over quarter, our prescriber base is growing. What we can conclude is that there is still a lot of room to continue this trend, both through our own activities and peer-to-peer recommendations. The heat map for Germany is visualizing how we are broadening sales of Pepaxti. Even though Germany is a scattered market and we have many customers, focusing on the highly populated areas is of utmost importance. These areas are the most crowded, with many pharma companies working to build awareness, and at the same time, many physicians are starting to restrict access to pharma. The challenge for us is that we are a small company and the only company launching a PDC. Well, there are many companies launching bispecifics. The opportunity, however, lies in the fact that we are unique. We have a unique product that truly delivers in real life, and where physicians gain experience, they appreciate Pepaxti and continue to use it. We have a resilient team. We are continuing to capture potential step by step. Italy is the second-largest market and was the strongest contributor to demand growth in the third quarter. Italy is an excellent example of how better understanding and awareness of Pepaxti, due to positive clinical experience already ahead of launch and with a more centralized prescriber base, can directly translate into a change in prescribing behavior when physicians now get access to Pepaxti. In the third quarter, we reached 90% access at the hospital level, and we now only have one high-potential region left to fully unlock. Looking at the uptake, the strong collaboration between our local field team and prescribers continues to drive performance, confirming that Pepaxti is making a meaningful difference for patients with encouraging real-world data from Italy, presented at the IMF Annual Meeting. This data highlights Pepaxti's effectiveness and tolerability in heavily pre-treated patients, further supporting uptake in peer-to-peer advocacy. In Italy, we have several investigators from our clinical development program, and we already have one investigator-initiated trial ongoing to close an important evidence gap to conclude on Italy. We have a strong start to the launch and a very promising foundation to build on. The heatmap visualizes the accumulated sales in variance sold per quarter and demonstrates the evolution of the Italian launch. We made our first sales in Q1, ahead of plan. We started to gain regional access in Q2, and we now have a fairly broad base of prescribers already in Q3. Spain stands out as a model of scalability for our commercial approach. We now have full regional access across the country. This means we have received orders from all the regions with multiple myeloma patients, marking another milestone achieved in Spain. We see scientific progress and launch-supporting activities advancing in the real world. Data from Spanish investigators, presented at the IMS annual Meeting, is the first of its kind, as all patients were previously treated with a bispecific antibody. Given that this drug class was recently launched, we don't have data from our clinical program on how these patients respond to Pepaxti. This is why it's so important and very encouraging to see that also in this patient group, Pepaxti's effectiveness and safety are confirmed. Just like in Italy. We have an investigator-initiated trial running, and in Spain, the focus is not only on Pepaxti but also on generating evidence in the clinic for our PDC platform, which can support our partnership discussions for other PDCs. The Spanish heatmap is visualizing full coverage of the country, and now it's about increasing the number of prescribers and ensuring even more patients are getting Pepaxti already in the fourth line to continue to accelerate the sales uptake for Spain. Moving to partnerships. In addition to the ongoing negotiations with Japanese partners, we continue to explore other deals. In fact, earlier this week I attended BIO-Europe, where we had many interesting and promising first discussions with different types of partners for both Pepaxti and our pipeline. There is an increased interest in exploring NK cell engagement. As a result of that, the T cell space is becoming crowded. In addition, indications with extremely high unmet needs like glioblastoma are of interest to many companies. In conclusion, it is not only us who find our pipeline strategically interesting, but many partners are also showing interest and want to understand the numerous opportunities we have at Oncopeptides. Even better discussions will continue, and we will keep the market updated on our current partnerships in South Korea. Our partners, CBO, have launched an access program for Pepaxti, providing full financial support to patients with triple-class refractory multiple myeloma. The program marks Pepaxti's first formal introduction in Asia beyond the clinical development program, with the first patient being treated at Seoul Saint Mary's Hospital. This initiative not only broadens Pepaxti's global footprint, but also underscores its recognition as a meaningful treatment option for patients with few remaining alternatives. The next step in South Korea is a regulatory submission, which our partner is working towards. We continue to build our PDC platform with Pepaxti leading the way. Serving as a proof of concept for the technology. In parallel, we are advancing our SPiKEs platform, focusing on engagement for oncology, hematology, and autoimmune diseases. Both programs illustrate our broader strategy to expand geographically, to form smart partnerships, and to innovate purposefully. I will not elaborate more on the pipeline right now, as I will get more into details in our upcoming capital markets update next week. And before I conclude, I would like to remind everyone about this event, which is on November the 13th from 9 to 12 Central European Time. It will be an online event broadcast here from Stockholm featuring leading myeloma experts and key stakeholders. Oncopeptides and I will give an update on the future of Oncopeptides, focusing on opportunities beyond what is required today. If you haven't already, I encourage you to register via our website. It will be an insightful session on both our commercial progress and scientific roadmap. To summarize, we have growth momentum. We are now delivering the fourth consecutive quarter of double-digit growth, tracking towards profitability by the end of 2026. We have a strong European foundation. Pepaxti is fully approved and reimbursed in key markets, representing about half of the total European opportunity, estimated at 1.5 billion SEK per year. We are expanding globally, with ongoing negotiations for Japan and established partnerships already in South Korea, Africa, and MENA. We are demonstrating scientific progress with RWD publications, guideline inclusion, and investigator-initiated trials in all markets, which are strengthening the party's position. We have an innovative pipeline with next-generation PDCs and SPiKEs platform that offers long-term growth potential in oncology, hematology, and immunology, and with solid execution, disciplined cost management, and growing market endorsement. Oncopeptides is well on track to deliver sustainable value creation. That concludes the presentation, and I would like to open up for questions.

Operator
23:46 - 24:03

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Richard Romanus
24:06 - 24:24

Good morning. I have a few questions. I'll take them one by one. The first one is, how do vacations impact sales exactly? Is that because sales representatives are on holiday? Since I assume patients are sick, they are going to continue being treated and doctors will continue treating them?

Sofia Heigis
24:26 - 25:36

Good morning, Richard. Thank you for the question. So it's actually a mix of several different aspects. One is that, just as you said, we are of course committed to giving our teams vacation. So our activity is reduced during certain periods over the summertime, like in all businesses. But it's also important to note that when the HCPs go on vacation, particularly in Germany, where there are office-based clinics, there are often fewer appointments available for these patients. So, they are having fewer patient visits, basically. And of course, if multiple myeloma patients are progressing and becoming acutely ill. They will still get treatment. And that is, of course, why we still see growth, because the physicians have learned to identify the patients for Pepaxti also without us being there as frequently. But I would argue that those are the two main factors. So it is really related to, let's say, HCP in the offices and, of course, lower activity from Oncopeptides.

Richard Romanus
25:38 - 25:58

All right. Then I had a question about costs, which decreased quarter over quarter. Is this going to carry over into the next quarters, or are Q1 and Q2 more representative of future costs?

Henrik Bergentoft
26:00 - 26:44

Thank you, Richard, for the question. So what we said is that we have established an organization that is in place to lead us to US profitability next year. And the benchmark we have set out is really the cost base for 2024, which would more or less continue onwards. Just to repeat what we had said before, but answering more directly to your question, Q1 and Q2 are more representative for the final quarter because Q3, by natural reasons, contains fewer activities, as compared to the fourth quarter.

Richard Romanus
26:46 - 27:17

Yeah, I understand. I also looked at the heat maps that you, Sophia, presented from the various countries. And I noticed, especially Italy seems to have a higher growth trend and uptake than Spain. And Spain followed them. Germany. Would you agree with this? This trend? You could extrapolate into 2026.

Sofia Heigis
27:17 - 29:09

I would definitely agree with that. That's a very good analysis made by you. And it comes, of course, with the experience ahead of the launch in the different countries where we have previously said that both Italy and Spain have more experience from a clinical development program in Spain. We had the chance to have quite a few patients in early access because, fortunately, we got the price negotiated really fast. In Italy, in addition to the clinical development program, we also had a quite comprehensive early access program, with close to 100 patients being included in that program. And that kind of recent superior experience in this current treatment landscape is really giving the prescribers confidence from the very start. Another aspect that I've mentioned many times before, which I believe bears repeating, is that both Spain and Italy are typically quicker in adopting treatments for multiple myeloma. Because they have a more centralized prescriber base. So they have fewer hematologist specialists prescribing for multiple myeloma, meaning that every physician sees more patients when it comes to Germany. That is a more scattered market, where we have office-based physicians, and they see all the different oncology and hematology indications, resulting in fewer patients per prescriber. And that is due to having basically no chance to prepare the launch based on Oncopeptides' financial situation when we got the price, which makes Germany stand out as a slower market. If you look at the launch uptake from the very start, Italy is certainly the strongest, with Spain following in between.

Richard Romanus
29:11 - 29:13

Okay, thank you for taking my questions.

Operator
29:17 - 29:37

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Unknown 1
29:38 - 29:45

Thank you. And there are a couple of written questions. The first one is, can you comment on October sales?

Sofia Heigis
29:46 - 31:16

I almost anticipated that question, as we did indeed comment on July sales in our last report, and we did so because we had the rights issue and wanted to be as transparent as possible. What I can say about October is that we are not really assessing sales on a monthly basis, but rather on a quarterly basis. But as I've shared throughout my presentation, we now have a very strong momentum in our markets. During the month of October, we had all the annual hematology society meetings. They take place in Spain, Italy, and Germany during this month and in late September. We also had IMS. The reason I'm mentioning this is because at IMS, you have all the global top KOLs in multiple myeloma, and in the annual meetings, you have the top KOLs from the countries as well as many prescribers. And that provides us a great opportunity to thoroughly assess our position, gain insights, and actively engage with these physicians. Overall, the outcome of those meetings, such as the symposia mentioned in Germany where we had to use the overflow group, which is actually quite rare, is very positive. In October, as I mentioned, we are seeing how the guidelines are starting to really take effect. We are seeing a very good sentiment in the markets.

Unknown 1
31:19 - 31:24

Question on the timeline for the SPiKEs platform. Is that something you can elaborate on?

Sofia Heigis
31:25 - 32:46

If you look at the launch uptake from the very start, Italy is for sure the strongest and then Spain in between. So when it comes to the SPiKEs platform, it's very novel, innovative, and new, as many of you know. That's why it requires more work in the pre-clinic, as the pre-clinical data will inform the approach in the clinic, which demands a much higher investment. So you want to do the right studies in pre-clinical to inform your clinical program, to really ensure that you make the right investment at that phase. And so we are currently still in pre-clinic. We also need to do formulation work because these are completely new assets. And when it comes to the timeline, I would refrain from commenting on that because it actually has to do with finances. Whether Oncopeptides would be able to finance it or if a partnership would be able to finance it remains a question. And when it comes to partnerships, we are having interesting discussions. But as we know, both from Oncopeptides and other companies, these types of discussions take time. So I would like to refrain from commenting on when we can enter because it really comes down to both the preclinical efforts we are making to build a strong direction for the clinic, as well as the financial situation.

Unknown 1
32:48 - 32:55

Thank you. And speaking of timelines. Last question. Do you expect that Japan will be concluded in 2025?

Sofia Heigis
32:56 - 33:58

So, as I mentioned, the discussions are advancing. Well, we are still advancing with the partner we have been talking about before, but we also have interest from several other partners with whom we are in discussions to ensure that we can conclude the best possible deal regarding the timeline. It's largely due to the internal processes and governance on the Japanese partner's side, and because Oncopeptides is a very small company, we operate, I would argue, at a fair speed. So we are not controlling the timeline. What we are controlling is that we are making progress, ensuring that we are working towards the best deal possible.

Unknown 1
33:59 - 34:05

With that, the Q&A session is concluded, and we would like to give some final remarks. Sophia.

Sofia Heigis
34:06 - 34:51

Yes, sure. So first of all, thank you everyone for joining us and listening to us today. With four consecutive quarters of strong growth, increasing scientific recognition, and a strengthened financial foundation, we are now entering the final quarter of 2025. We are now entering the final quarter of 2025. With both focus and confidence, we'll continue to execute with discipline. We will continue to work to expand access to Pepaxti across Europe and in the rest of the world, and we are still progressing towards our profitability target for 2026. And I am looking forward to seeing many of you again at our Capital Market update next week on November 13th. So thank you so much and have a great day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…